Imugene - Anti-Tumour Vaccine Trial To Start Mid-2016
Edison | Feb 22, 2016 06:59AM ET
Anti-tumour vaccine trial to start mid-2016
Imugene (AX:IMU) will test its reformulated therapeutic cancer vaccine, HER-Vaxx, in gastric cancer at trial sites in Asia. The Phase Ib/II trial is expected to start in mid-2016. HER-Vaxx aims to replicate or improve on the combination of two proven therapeutic antibodies, Herceptin and Perjeta (Roche). Imugene aims to gain a major pharma deal following Phase II data in the buoyant cancer immunotherapy area. A$3.0m raised in October gives it sufficient funds to undertake the Phase Ib component of the trial.
Phase Ib/II gastric cancer trial to be based in Asia
Imugene is moving its upcoming Phase Ib/II study to trial sites in Asia. The previous strategy had been to do the trial in Australia and Eastern Europe, but government plans to subsidise Herceptin treatment for HER2 positive gastric cancer patients would have made recruitment in Australia difficult. Novotech has been appointed as the CRO to manage the trial at a number of leading cancer centres in Asia. The level of HER2 antibodies produced after treatment with HER-Vaxx will be measured in the Phase Ib trial, which will be an important pointer towards potential efficacy.
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.